



## Pharmacy

### Medicaid Fee-for-Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program



**Contact Details:**

**1-800-343-9000**  
[emednyalert@csra.com](mailto:emednyalert@csra.com)

### Medicaid Fee-for-Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

**Effective 10/23/2018**, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- **Suboxone 8mg/2mg film will be ADDED** to the program

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

### **IMPORTANT BILLING INFORMATION**

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of "1"; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

### List of Brand Name Drugs included in this program\* (Updated):10/23/18

Adderall XR	Fosrenol chew tablet	Tegretol suspension
Aggrenox	Gleevec	Tobradex suspension
Alphagan P 0.15%	Hepsera	Transderm-Scop
Butrans	Kapvay	Trizivir
Catapres-TTS	Lexiva tablet	Voltaren Gel
Cellcept suspension	Norvir tablet	Vigamox
Copaxone 20mg	Protopic	Xeloda

Diastat	Pulmicort respule 1mg	Xenazine
Exelon Patch	Retin-A cream	Zyflo CR
Focalin	<b>Suboxone 8mg/2mg film</b>	
Focalin XR	Sustiva tablet	

\*List is subject to change

**Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.**

If you are having problems viewing content within this newsletter, please email [emednyalert@csra.com](mailto:emednyalert@csra.com) for further assistance

The Department has attempted to ensure that the information contained in these notifications is as accurate as possible. However, no e-mail transmittals or materials provided are intended to constitute legal or medical advice.